^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CD70 expression

i
Other names: CD70, CD27L, CD27LG, TNFSF7
Entrez ID:
Related biomarkers:
12d
Simultaneous Expression of CD70 and POSTN in Cancer-Associated Fibroblasts Predicts Worse Survival of Colorectal Cancer Patients. (PubMed, Int J Mol Sci)
On the basis of our observations, CD70 and POSTN immunohistochemistry can be used in the prognostication of CRC patients. CRC CAFs may be a promising target in the treatment of CRC patients.
Journal
|
CD70 (CD70 Molecule) • ACTA2 (Actin Alpha 2 Smooth Muscle) • POSTN (Periostin)
|
CD70 expression
1m
Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents. (PubMed, Virchows Arch)
In this study, we employed routine diagnostic techniques, such as immunohistochemistry and flow cytometry, to investigate the expression of CD70 in bone marrow samples from treatment-naïve and relapsed AML patients after hypomethylating agents (HMA). Also, we evaluated the impact of HMA on CD70 expression and examined CD70 expression in various leukemic cell subsets and normal hematopoietic progenitors.
Journal • IO biomarker
|
CD70 (CD70 Molecule) • CD27 (CD27 Molecule)
|
CD70 expression
2ms
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts. (PubMed, J Hematol Oncol)
We disclose CD70 as an attractive target both in hematological and solid tumors. IL-15 armored CAR NK cells act as potent effectors to eliminate these CD70+ cells. They can target both tumor cells and CAFs in patients with CRC and PDAC, and potentially other desmoplastic solid tumors.
Journal • Pan tumor
|
CD70 (CD70 Molecule) • IL15 (Interleukin 15)
|
CD70 expression
2ms
Soluble CD27 as a predictive biomarker for intra-tumoral CD70/CD27 interaction in nasopharyngeal carcinoma. (PubMed, Cancer Sci)
Furthermore, positive expression of CD70 by NPC cells was significantly correlated with EBV infection. Our results suggest that CD70/CD27-targeted immunotherapies may be promising treatment options and that sCD27 may become an essential tool for evaluating the applicability of these therapies by predicting the intratumoral CD70/CD27 interaction in NPC.
Journal • IO biomarker
|
CD70 (CD70 Molecule) • CD27 (CD27 Molecule)
|
CD70 expression • CD27 expression
3ms
CD70 is Consistently Expressed in Primary and Metastatic Clear Cell Renal Cell Carcinoma. (PubMed, Clin Genitourin Cancer)
Our findings validated CD70 as a promising therapeutic target for patients with metastatic clear cell renal cell carcinoma. The utility of primary tumor tissue as surrogate samples for metastatic clear cell carcinoma awaits future CD70-targeted clinical trials.
Journal • Metastases
|
CD70 (CD70 Molecule)
|
CD70 expression
4ms
CD70 CXCR2-Modified CAR T-Cells Against Acute Myeloid Leukemia (TCT-ASTCT-CIBMTR 2024)
8R-70CAR T cells are able to specifically recognize and kill CD70+ AML cells, and cytotoxicity may be augmented by enhancing CD70 expression with azacytidine pre-treatment. A LLS tumoroid model can aid in 3D visualization of 8R-70CAR T cells interactions AML cells. These findings combined with safety data obtained from our ongoing phase I clinical trial for adults with glioblastoma (NCT05353530) will support expansion of our existing IND to treat patients with AML using our novel 8R-70CAR.
CAR T-Cell Therapy
|
IFNG (Interferon, gamma) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CD70 (CD70 Molecule) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
|
MLL rearrangement • CD70 expression • IFNG expression • CXCL8 expression • CXCL8 overexpression
|
azacitidine • 8R-70CAR T
4ms
Evaluation of CD70 Chimeric Antigen Receptor T (CAR-T) Cells As a Potential Treatment for Non-Hodgkin's Lymphoma: A Preclinical Study (ASH 2023)
We successfully generated CD70 CAR-T cells based on a VHH nanobody (11C9) and CD19 CAR-T cells based on murine scFv (FMC63) following the exact manufacturing protocols used for phase I and phase II clinical trial products respectively... Our results indicate that CD70 CAR-T cell is potential treatment for NHL. We will conduct an investigation of single and dual CD70 CAR-T on treatment of lymphoma especially for CD19 negative NHL.
Preclinical • CAR T-Cell Therapy • IO biomarker
|
TNFA (Tumor Necrosis Factor-Alpha) • CD70 (CD70 Molecule)
|
CD70 expression
4ms
Bioconjugated Liquid-Like Solid Enhances Characterization of Solid Tumor - Chimeric Antigen Receptor T Cell Interactions. (PubMed, Acta Biomater)
To better study these specialized CAR T cells in this context, we have developed an innovative in vitro three-dimensional model that promises to dissect the interactions between tumors and CAR T cells at the single-cell level. Our findings provide valuable insights into the complex dynamics of CAR T cell function in solid tumors, informing future research and development in this promising cancer treatment approach.
Journal • CAR T-Cell Therapy • IO biomarker
|
CD70 (CD70 Molecule)
|
CD70 expression
4ms
LINC00887 regulates malignant progression and T-cell chemotaxis in clear cell renal cell carcinoma by activating CD70 via recruitment of SPI1. (PubMed, Gene)
LINC00887, by recruiting SPI1, activated CD70 transcription, thereby propelling malignant progression and cell stemness and suppressing T cell chemotaxis in ccRCC. Based on our findings, we believed that the LINC00887-SPI1-CD70 regulatory axis had the potential to be a critical breakthrough for treating ccRCC.
Journal
|
CD70 (CD70 Molecule) • SPI1 (Spi-1 Proto-Oncogene)
|
CD70 expression
5ms
CD27/CD70 pathway activation in primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder. (PubMed, J Pathol)
© 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • CD70 (CD70 Molecule) • CD4 (CD4 Molecule) • CD27 (CD27 Molecule)
|
CD70 expression • CD27 expression • PD-1 positive
5ms
Targeting T-Cell Lymphoma Using CD70-Directed Cord Blood-Derived CAR-NK Cells (ASH 2023)
Taken together, our findings validate CD70 as a promising target for TCL treatment using CAR NK cells. Our approach provides a solid foundation for the clinical translation of CD70-targeting CAR NK-cell therapy for patients with TCL.
IO biomarker
|
ALK (Anaplastic lymphoma kinase) • TNFA (Tumor Necrosis Factor-Alpha) • IL2RA (Interleukin 2 receptor, alpha) • CD70 (CD70 Molecule) • CD27 (CD27 Molecule) • LAMP1 (Lysosomal Associated Membrane Protein 1) • GZMB (Granzyme B) • IL15 (Interleukin 15)
|
ALK fusion • CD70 expression • CD19 expression • NPM-ALK fusion
5ms
CD70 CAR NK Cells in the Treatment of Multiple Myeloma (ASH 2023)
In addition, using immunohistological staining, we found that CD70 was expressed on 10 of 10 patients who had progressed on BCMA targeted therapies (seven who had progressed on belantamab mafodotin, an antibody drug conjugate, three who had progressed on idecabtagene vicleucel, a BCMA CAR-T), suggesting that CD70 could be a viable target in patients who have failed BCMA targeted therapy. In summary, we were able to demonstrate that CD70 can be a feasible target for the treatment of multiple myeloma, including in patients who have failed BCMA targeted therapy. Based on these results, we have initiated a Phase I/II clinical trial (NCT05092451) that is currently recruiting.
IO biomarker
|
CD70 (CD70 Molecule)
|
CD70 expression
|
Blenrep (belantamab mafodotin-blmf) • Abecma (idecabtagene vicleucel)
5ms
Discovery and Development of CD70 As a Cellular Therapy Target in High Risk Multiple Myeloma (ASH 2023)
Finally, we also demonstrated that treatment with the hypomethylating agent azacytidine can drive increased CD70 expression, similar to that shown in AML models. Taken together, targeting CD70 appears to be a highly promising cellular therapeutic strategy for MM, with particularly high utility in high-risk patients after BCMA CAR-T relapse. We are continuing preclinical and future clinical development of this CAR-T strategy, using our natural ligand CD27 design with extended in vivo persistence.
IO biomarker
|
CD8 (cluster of differentiation 8) • PAX5 (Paired Box 5) • CD70 (CD70 Molecule) • CD4 (CD4 Molecule) • SDC1 (Syndecan 1) • CD27 (CD27 Molecule) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2) • TFAP2A (Transcription Factor AP-2 Alpha)
|
CD70 expression • SDC1 positive • CD70 overexpression
|
azacitidine
5ms
CD70/CD27 Signaling Promotes Expansion of Clonal Plasma Cells in Multiple Myeloma and Is a Promising Therapeutic Target in Advanced Disease (ASH 2023)
Moreover, different monoclonal antibodies (Abs) and Ab-derivates were tested including a CD70 blocking antibody (αCD70) and an antibody-dependent cell-mediated cytotoxicity (ADCC) optimized antibody (cusatuzumab, ArgenX) that activates FcγR-expressing effector cells to assess the therapeutic potential of targeting CD70 in MM... Our results indicate that CD70-expressing MM cells have a stem-cell like phenotype and propagate the disease. Targeting CD70 is a promising new therapy especially in advanced disease.
IO biomarker • Metastases
|
CD70 (CD70 Molecule) • CD27 (CD27 Molecule) • MKI67 (Marker of proliferation Ki-67)
|
CD70 expression • CD27 expression • CD70 overexpression
|
cusatuzumab (ARGX-110)
5ms
The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling. (PubMed, Front Oncol)
In vitro cell-based assays demonstrated that IMM40H had considerably stronger CD70-binding affinity than competitor anti-CD70 antibodies, including cusatuzumab, which enabled it to block the interaction of between CD70 and CD27 more effectively...A strong synergistic effect between IMM01 (SIRPα-Fc fusion protein) and IMM40H was recorded in Burkitt's lymphoma Raji and renal carcinoma cell A498 tumor models...IMM40H is a high-affinity humanized IgG1 specifically targeting the CD70 monoclonal antibody with enhanced Fc-dependent activities. IMM40H has a dual mechanism of action: inducing cytotoxicity against CD70+ tumor cells via various effector functions (ADCC, ADCP and CDC) and obstructs the proliferation and activation of Tregs by inhibiting CD70/CD27 signaling.
Journal • IO biomarker
|
CD70 (CD70 Molecule) • CD27 (CD27 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
|
CD70 expression • CD27 expression
|
cusatuzumab (ARGX-110) • IMM01 • IMM40H
6ms
Radiation Therapy Sensitizes Head-and-Neck Cancer Cells to Killing by Chimeric Antigen Receptor (CAR)-NK Cells Targeting CD70. (PubMed, Int J Radiat Oncol Biol Phys)
This work represents the first preclinical study to identify the synergy of RT and CAR-NK cell therapy in solid tumors and is the first demonstration of CAR-NK cell activity against human HNSCCs. We show significantly enhanced potency of CAR-NK cells against irradiated tumor cells in vitro. Collectively, this research will be vital to guide efforts expanding into other target antigens and tumor types.
Journal • IO biomarker
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD70 (CD70 Molecule) • CD27 (CD27 Molecule) • LAMP1 (Lysosomal Associated Membrane Protein 1)
|
CD70 expression • IFNG expression • LAMP1 expression
6ms
Overview of CD70 as a Potential Therapeutic Target for Osteosarcoma. (PubMed, J Immunol)
Nonetheless, CD70-based clinical trials are currently ongoing and are preliminarily showing promising results for patients with osteosarcoma. The present review sheds light on the recent literature on CD70 as it relates to osteosarcoma and highlights the benefits and challenges of targeting this pathway.
Journal
|
CD70 (CD70 Molecule)
|
CD70 expression
7ms
PAX5 and CD70 are expressed in thymic carcinoma but not in atypical thymoma (WHO type B3 thymoma): an immunohistochemical analysis of 60 cases. (PubMed, J Clin Pathol)
Among the markers explored, only PAX5 and CD70 appear to be differentially expressed and are predominantly restricted to thymic carcinomas. Therefore, in small biopsy specimens and in resections in which the morphological features remain equivocal, application of these particular stains may facilitate separation of thymic carcinoma and atypical thymoma.
Journal
|
PAX5 (Paired Box 5) • CD70 (CD70 Molecule) • KRT5 (Keratin 5) • PAX2 (Paired Box 2) • PAX8 (Paired box 8)
|
CD70 expression
7ms
Revealing the impact of CD70 expression on the manufacture and functions of CAR-70 T-cells based on single-cell transcriptomics. (PubMed, Cancer Immunol Immunother)
This study evidenced that CD70 stimulation during manufacturing process induced early exhaustion of CAR-70 T-cells. Knocking-out CD70 in T-cells prevented the exhaustion and led to a better-quality CAR-70 T-cell product. Our research will contribute to good engineering CAR T-cells targeting self-expressed antigens.
Journal
|
CD70 (CD70 Molecule)
|
CD70 expression
7ms
METTL3 inhibition induced by M2 macrophage-derived extracellular vesicles drives anti-PD-1 therapy resistance via M6A-CD70-mediated immune suppression in thyroid cancer. (PubMed, Cell Death Differ)
Furthermore, blocking CD70 using cusatuzumab, a high-affinity monoclonal antibody, reversed the anti-PD-1 therapy resistance induced by M2 EVs in vivo. Finally, we demonstrated that METTL3 expression negatively correlated with CD70 expression and M2 macrophages and Tregs infiltration in PTC and ATC tissues. Our findings provide new insights into developing novel therapies for advanced PTC and ATC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD70 (CD70 Molecule) • MIR21 (MicroRNA 21) • METTL3 (Methyltransferase Like 3) • YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein 2)
|
CD70 expression
|
cusatuzumab (ARGX-110)
7ms
New P1 trial • Metastases
|
IL6 (Interleukin 6) • CD70 (CD70 Molecule)
|
CD70 expression
|
cyclophosphamide • CD70 CAR-T
7ms
Radiation Therapy Sensitizes Head-and-Neck Cancer Cells to Killing by Chimeric Antigen Receptor (CAR)-NK Cells Targeting CD70 (ASTRO 2023)
This work represents the first preclinical study to identify the synergy of RT and CAR-NK cell therapy in solid tumors and is the first demonstration of CAR-NK cell activity against human HNSCCs. We show significantly enhanced potency of CAR-NK cells against irradiated tumor cells in vitro . Collectively, this research will be vital to guide efforts expanding into other target antigens and tumor types.
IO biomarker
|
TNFA (Tumor Necrosis Factor-Alpha) • CD70 (CD70 Molecule) • CD27 (CD27 Molecule) • LAMP1 (Lysosomal Associated Membrane Protein 1)
|
CD70 expression • LAMP1 expression
8ms
TARGETING CD70 USING CAR NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA (CTOS 2023)
CD70 has immunotherapy potential against OS. CD70 CAR NK cells have increased cytolytic activity against OS cells in vitro. The cytolytic activity may be influenced by the release of specific cytokines.
IO biomarker
|
CD70 (CD70 Molecule)
|
CD70 expression
8ms
Preclinical characterization of ARX305: A next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers (ESMO 2023)
Conclusions In summary, the highly selective and potent anti-tumor activity in multiple tumor types and wide pre-clinical therapeutic index of ARX305 support clinical evaluation of this next generation anti-CD70 ADC. ARX305 is currently in a phase 1 dose-escalation study in China.
Preclinical
|
CD70 (CD70 Molecule)
|
CD70 expression
|
ARX305
9ms
New P1/2 trial • CAR T-Cell Therapy
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD70 (CD70 Molecule) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
CD70 expression
|
cyclophosphamide • CD70 CAR-T
9ms
New P1/2 trial
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD70 (CD70 Molecule) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
CD70 expression
|
albumin-bound paclitaxel • cyclophosphamide • CD70 CAR-T
10ms
Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia. (PubMed, Cancer Immunol Immunother)
CD70 expression in AML blasts was not fully supportive of its role in AML targeted therapy as reported. The combinational use of Chidamide and Decitabine with nb70CAR-T could provide a new potential for the treatment of AML.
Preclinical • Journal • CAR T-Cell Therapy • IO biomarker
|
CD70 (CD70 Molecule) • CD27 (CD27 Molecule)
|
CD70 expression
|
decitabine • Epidaza (chidamide)
10ms
Comparative expression analysis of immune-related markers in surgically resected lung neuroendocrine neoplasms. (PubMed, Lung Cancer)
By providing insights into the widely divergent immunologic profiles of LNENs, our results might serve as a basis for the development of novel immunotherapy-related approaches in these devastating malignancies.
Journal • IO biomarker
|
LAG3 (Lymphocyte Activating 3) • CD47 (CD47 Molecule) • CD70 (CD70 Molecule) • TNFRSF9 (TNF Receptor Superfamily Member 9) • ICOS (Inducible T Cell Costimulator) • CD27 (CD27 Molecule) • CD40 (CD40 Molecule)
|
CD70 expression • LAG3 expression • CD27 expression • CD40 expression
11ms
CD70/CD27 SIGNALING PROMOTES THE EXPANSION OF CLONAL PLASMA CELL SUBSETS IN MULTIPLE MYELOMA (EHA 2023)
In this regard, different Abs and Ab-derivates were tested including a CD70 blocking antibody (αCD70) and an antibody-dependent cell-mediated cytotoxicity (ADCC) optimized antibody (cusatuzumab) that activates FcγR-expressing effector cells... Although the treatment options of MM have rapidly increased during the last years, MM remains an incurable disease that ultimately leads to death. Our results indicate that especially advanced MM stages express high levels of CD70. In addition, our results indicate that CD70/CD27 cell-autonomous signaling contributes to disease progression and therapy resistance and identifies CD70 as potential target in MM.
IO biomarker
|
CD70 (CD70 Molecule) • CD27 (CD27 Molecule) • MKI67 (Marker of proliferation Ki-67)
|
CD70 expression • CD27 expression • CD70 overexpression
|
cusatuzumab (ARGX-110)
11ms
ANTI-LEUKEMIA ACTIVITY OF CD70-DIRECTED IMMUNOTHERAPY IN B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (EHA 2023)
We show increased CD70 surface expression on BCP-ALL cells associated with inferior outcome. Using CD70- directed antibodies, we characterize CD70 as immunotherapeutic target in vitro , ex vivo and in vivo showing anti- leukemia activity including effective reduction of leukemia loads in a pre-clinical patient-derived xenograft model of CD70-positive BCP-ALL. Acute lymphoblastic leukemia, Immunotherapy, Antibody targeting
IO biomarker
|
TNFA (Tumor Necrosis Factor-Alpha) • CD70 (CD70 Molecule) • CD27 (CD27 Molecule)
|
CD70 expression
11ms
Site-specific Ga-labeled nanobody for PET imaging of CD70 expression in preclinical tumor models. (PubMed, EJNMMI Radiopharm Chem)
[Ga]Ga-NOTA-anti-CD70 VHH showed excellent in vivo targeting of CD70 in human cancer xenografts. PET imaging using this radioimmunoconjugate holds promise as a non-invasive method to identify and longitudinally follow-up patients who will benefit most from anti-CD70 therapies.
Preclinical • Journal • IO biomarker
|
TNFA (Tumor Necrosis Factor-Alpha) • CD70 (CD70 Molecule) • CD27 (CD27 Molecule)
|
CD70 expression
11ms
VHH-based chimeric antigen receptor T cells against CD70 to eliminate primary and re-challenge renal cell carcinoma tumors in preclinical study. (ASCO 2023)
These CAR constructs include 4 VHH sequences and a human scFv containing VH and VL derived from cusatuzumab... Our results indicate a promising VHH-based CD70 CAR-T cells for RCC therapy, supporting further development for future clinical trial and application.
Preclinical • CAR T-Cell Therapy
|
CD70 (CD70 Molecule) • IL2 (Interleukin 2)
|
CD70 expression
|
cusatuzumab (ARGX-110)
11ms
IL-2 Preferentially Expands a Less Functional, CD27-Negative CAR T Cell Subset and Compromises Antitumor Potency (ASGCT 2023)
These results provided the cellular mechanism of IL-2-driven differentiation when expanding therapeutic T cells, revealing the critical need to refine manufacturing procedures and preserve CD27-expressing CAR T cells. This work also suggested the potential of CD27 as a biomarker for the functional quality of CAR T cell products.
CAR T-Cell Therapy • IO biomarker
|
IL2RA (Interleukin 2 receptor, alpha) • CD70 (CD70 Molecule) • IL2 (Interleukin 2) • CD27 (CD27 Molecule) • IL15 (Interleukin 15)
|
CD70 expression • CD27 expression • IL2 expression
11ms
ADI-270: An Armored Allogeneic "Off-the-Shelf" CAR γδ T Cell Therapy Targeting CD70+ Cancers (ASGCT 2023)
In summary, ADI-270 demonstrates preclinical proof-of-concept of an armored allogeneic CD70 γδ CAR T cell therapy utilizing the CD27 natural receptor CAR format for targeting CD70+ cancers. These data support continued development and further investigation of ADI-270 in the clinic.
IO biomarker
|
CD70 (CD70 Molecule) • CD27 (CD27 Molecule) • TGFB1 (Transforming Growth Factor Beta 1)
|
CD70 expression • CD27 expression
12ms
Targeting CD70 using CAR NK cells to enhance NK cells cytolytic effect against osteosarcoma (P323) (IMMUNOLOGY 2023)
 CD70 has immunotherapy potential against OS. CD70 CAR NK cells have increased cytolytic activity against OS cells in vitro. Cytolytic activity may be influenced by the release of specific cytokines.
IO biomarker
|
CD70 (CD70 Molecule)
|
CD70 expression
12ms
CD70 and PD-L1 (CD274) co-expression predicts poor clinical outcomes in patients with pleural mesothelioma. (PubMed, J Pathol Clin Res)
Collectively, these findings suggest that CD70 and PD-L1 both enhance the malignant phenotypes of PM and diminish anti-tumour immune responses. Based on our observations, combination therapy targeting these signalling pathways might be useful in patients with PM.
Clinical data • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD70 (CD70 Molecule) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CD27 (CD27 Molecule) • CD68 (CD68 Molecule) • CDH2 (Cadherin 2) • FOXP3 (Forkhead Box P3)
|
PD-L1 expression • CD70 expression
1year
Preclinical development of a monoclonal antibody targeting CD70 as cancer immunotherapy (AACR 2023)
Notably, in a U266 multiple myeloma model, IMM40H, at the dose of 0.3 mg/kg, completely inhibited tumor growth in a way that therapeutic effects appeared significantly earlier than that of cusatuzumab at a higher dose of 1 mg/kg. Therapeutic effects of IMM40H at the dose of 3 mg/kg also appeared earlier than that of bortezomib at the dose of 0.5 mg/kg. Interestingly, combination of IMM40H and IMM01 (a SIRPα-IgG1 Fc fusion protein targeting CD47) generated significant therapeutic synergy in models of A498 kidney cancer and Raji lymphoma...IND of IMM40H has been approved in China and US. This antibody is now in a phase 1 study in patients with advanced malignancies expressing CD70.
Preclinical • IO biomarker
|
CD47 (CD47 Molecule) • CD70 (CD70 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
|
CD70 expression
|
bortezomib • cusatuzumab (ARGX-110) • IMM01 • IMM40H
1year
Preclinical characterization of ARX305, a next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers (AACR 2023)
In summary, the highly potent anti-tumor activity in multiple tumor types and wide therapeutic index of ARX305 support clinical evaluation of this next generation anti-CD70 ADC. ARX305 is currently in a Phase 1 dose escalation study in China, and the IND in the United States is open.
Preclinical
|
CD70 (CD70 Molecule)
|
CD70 expression • CD70 overexpression
|
ARX305
1year
CD70 HIT T cells overcome tumor antigen heterogeneity in renal cell carcinoma (AACR 2023)
This represents a significant advance for the development of a potentially effective cellular therapy for RCC, which may be applicable to other aggressive CD70-positive tumors like ovarian and pancreatic cancers. Our findings underscore the critical importance of assessing antigen expression in a quantitative manner to determine if antigens are truly absent or present at very low levels, in which case they may be responsive to an engineered antigen-sensitive immune cell as afforded by the HIT receptor.
IO biomarker
|
CD70 (CD70 Molecule) • CA9 (Carbonic anhydrase 9)
|
CD70 expression • CA9 expression